Corporate Venture Takes Center Stage
This article was originally published in Start Up
Executive Summary
Corporate venture groups are poised to become one of the main sources of funding for early-stage biotechs thanks to the current economic climate. Even if corporate venture groups invest at the same levels as previous years, some industry veterans believe they could play a role in up to half of the early-stage financings this year, largely because the traditional sources of financing--the public market and venture capital groups flush with cash--have disappeared. And the new vigor of corporate venture offers big benefits to both small biotechs and Big Pharma.
You may also be interested in...
GSK Will Be A Limited Partner In Sanderling Ventures’ New Fund
The pharma pledges $50 million to the California firm’s new seventh round, which it anticipates closing more than eight years after its sixth. For GSK, it’s the latest tie-up with a VC firm as part of a regional investment strategy.
Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs
Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.
Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs
Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.